Botox and Fillers: Blood Thinners, Supplements, and What to Stop Before Treatment
An evidence-based pre-treatment guide on blood thinners and supplements for Botox and fillers, analyzing bruising mechanisms, prescription protocols, and technique…
Neuromodulators, dermal fillers, biostimulators, and the longevity question. Label-first, comparison-shaped.
An evidence-based pre-treatment guide on blood thinners and supplements for Botox and fillers, analyzing bruising mechanisms, prescription protocols, and technique…
A comprehensive regulatory dossier analyzing Merz Aesthetics' portfolio, Xeomin's BLA registration, Radiesse's and Belotero's PMA history, and Ultherapy PRIME's FDA…
The FDA's proposed exclusion of semaglutide and tirzepatide from the 503B Bulks List will end industrial GLP-1 compounding in 2026. A guide to legal timelines and…
Cosmetic Botox is excluded from HSA/FSA funds, but therapeutic Botox for migraine, hyperhidrosis, or TMJ qualifies with an LMN and proper coding. A detailed regulatory…
FDA warnings on needle-free dermal filler devices (Hyaluron Pens). High-pressure jet injection carries severe risks of skin necrosis, permanent blindness, and clinical…
An analysis of 10 FDA injectable labels: every botulinum toxin carries the same boxed warning, while Kybella does not. A plain map of what the prescribing information…
Bellafill is the only FDA-approved permanent dermal filler in the US — PMMA microspheres that stay for years. What it is approved for, who is not a candidate, and why it…
Full FAERS analysis of 1,968 deoxycholic-acid (Kybella) reports: nerve-injury terms lead, off-label and 'drug ineffective' rank high, and a paradoxical fat-growth signal…
Regenerative aesthetics mapped from 77 trials and the FDA record: PRP leads the research, exosomes and polynucleotides have no U.S. approval, and unapproved stem-cell…
22,242 FDA MAUDE reports for dermal fillers (product code LMH): the Juvéderm family leads at 55%, HA fillers drive 72% of all reports, and a 2025 surge pushed annual…